Skip to main content

Meeting Highlights

Meeting Highlights

Breast Cancer, ESMO Highlights, CDK4/6 Inhibitors

Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care

Meeting Highlights

ASCO Highlights

FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs

Meeting Highlights

ASH Highlights

Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies

Charles Bankhead

Charles Bankhead, Medical Writer

Meeting Highlights

ASH Highlights, Venetoclax

MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL

Phoebe Starr, Medical Writer

Meeting Highlights

ASH Highlights, Venetoclax

Researchers Identify First Mutation to Explain Resistance to Venetoclax

Phoebe Starr, Medical Writer

Meeting Highlights

ASH Highlights, Immunotherapy

Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy

Phoebe Starr, Medical Writer

Meeting Highlights

ASH Highlights, Lymphoma

Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas

Phoebe Starr, Medical Writer

Meeting Highlights

ASH Highlights, Leukemia

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL

Wayne Kuznar, Medical Writer

Meeting Highlights

ASH Highlights

Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML

Meeting Highlights

ASH Highlights

Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation–Positive, Newly Diagnosed AML

Page 7 of 8
Results 61 - 70 of 72